Many countries using sensitive screening methods for detection of carriage of methicillinresistant Staphylococcus aureus (MRSA) have a sustained low incidence of MRSA infections. For diagnostic laboratories with high sample volumes, MRSA screening requires stability, low maintenance and high performance at a low cost. Herein we designed oligonucleotides for a new nuc targeted hydrolysis probe PCR to replace the standard in-house nuc SybrGreen PCR assay. This new, more time-efficient, PCR assay resulted in a 40% increase in daily sample capacity, with maintained high specificity and sensitivity. The assay was also able to detect Staphylococcus aureus clonal cluster 75 (CC75) lineage strains, recently re-classified as Staphylococcus argenteus, with a sensitivity considerably increased compared to our previous assay. While awaiting consensus if the CC75 lineage of S. aureus should be considered as S. argenteus, and whether methicillin-resistant S. argenteus should be included in the MRSA definition, many diagnostic laboratories need to update their MRSA assay sensitivity/specificity towards this lineage/species. The MRSA screening assay presented in this manuscript is comprised of nuc oligonucleotides separately targeting S. aureus and CC75 lineage strains/S. argenteus, thus providing high user flexibility for the detection of CC75 lineage strains/S. argenteus.
Introduction
Methicillin resistant Staphylococcus aureus (MRSA) is a multidrug resistant pathogen that causes both nosocomial and community-acquired infections worldwide. Rapid and accurate detection of MRSA is essential to enable early treatment and prevent further transmission of this pathogen. In Sweden, a relatively high percentage of patients admitted to hospitals are screened for the presence of MRSA. Although it is not possible to show a causative link a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Herein, we introduce a new nuc targeted hydrolysis probe PCR to replace the SybrGreen PCR in the primary detection step of the MRSA screening workflow, described in Fig 1. The aim was to increase the sample capacity while maintaining a low cost. Besides upholding present high specificity and sensitivity for MRSA, the hydrolysis probe PCR also needed to include, but not differentiate, detection of the CC75-lineage of S. aureus/S. argenteus with high sensitivity.
Materials & methods

Bacterial strains, clinical samples and culture conditions
Reference strains have been collected from the American Type Culture Collection (ATCC), the Culture Collection, University of Gothenburg (CCUG) and the National Collection of Type Cultures (NCTC).
S. aureus strains used in this study (n = 25) consisted of a combination of reference strains and clinical isolates. The reference strains (n = 14) were as follows: ATCC25923, ATCC29213, ATCC6538, ATCC700699, CCUG31966, CCUG4151, CCUG41582, CCUG46147, CCUG29318, CCUG32115, CCUG32607, CCUG33290, CCUG33735 and CCUG46923. Clinical strains isolated from wound, nose, throat, urine, hair follicle, abscess, blood and sputum (n = 9), provided by the department of Clinical Microbiology at Ö rebro University Hospital, were also tested. The remaining two clinical isolates, isolated from wound in 2003 and throat swab in 2007, originated from the department of Clinical Microbiology at Karolinska University Hospital (identified as MRSA using the workflow in Fig 1) . One of these isolates was MRSA strain CC75-08, a CC75 lineage/S. argenteus strain.
A comprehensive study of organisms other than S. aureus (n = 35) were tested for specificity. For strain information, see S1 Table. A total number of 629 clinical samples sent to our laboratory for MRSA screening in 2013, originating from swabs from wound, nose, throat, perineum, skin, injection sites, urine, ostomy and catheter sites, were tested for nuc presence. Samples were inoculated in a selective broth containing Isosensitest broth 2.3% (ThermoFisher, Basingstoke, UK), Aztreonam 8μg/mL (SigmaAldrich, Schnelldorf, Germany), Cefoxitin 4 μg/mL (Sigma-Aldrich) and Colistin 8 μg/mL (Sigma-Aldrich), followed by incubation overnight at 35˚C [2, 3, 10] prior to DNA extraction.
Sample cultures positive for the nuc gene in the primary detection step were subcultured on SAID CHROMagar TM plates (CHROMagar, Paris, France) and complemented with a cefoxitin disc (30μg, ThermoFisher) in the primary streak. The plates were incubated at 35˚C overnight before DNA isolation and molecular detection of nuc and mecA from single colonies. For determination of colony-forming units (CFU) in sensitivity tests, bacterial suspensions were plated on 5% blood agar plates and incubated at 35˚C overnight before counting.
DNA extraction
Manual extraction. DNA from bacterial strains was isolated using manual heating extraction. Colonies were resuspended in nuclease free water and DNA was then extracted by heating the bacterial suspensions to 94˚C for 15 minutes in a block heater. The cell remnants were pelleted by centrifugation at 14000 rpm, leaving the template DNA in the supernatant.
Automated extraction, BioRobot M48. The BioRobot M48 using the MagAttract DNA mini M48 kit (both from Qiagen, Hilden, Germany) was used for specificity and sensitivity studies. DNA extraction, based on silica coated magnetic beads, was performed according to the manufacturer's instructions.
Automated extraction, Xiril robot. For clinical sample broth cultures, DNA was isolated using automated extraction. Broths incubated overnight were extracted using the four-channeled Xiril X100 robot or the eight-channel Xiril Neon100 robot (Xiril AG, Hombrechtikon, Switzerland). The same extraction protocol was used for both robots, starting with broth removal by filtration using styrene Multiscreen HTS Filter Plates (Merck Millipore, Billerica, MA, USA). The cells were thereafter resuspended in water and lysed by heating the cell suspensions to 94˚C for 15 minutes. DNA template was obtained by a second filtration step separating DNA from cell remnants.
Real-time PCR
Primary detection oligonucleotides. All oligonucleotides used in this study, presented in Table 1 , were ordered with a purity of cartridge grade or higher.
Primary detection amplification conditions. Amplification of the nuc gene using SybrGreen was carried out in a 20 μL reaction mix using 2x Fast SybrGreen Master Mix (ThermoFisher), 0,5 μM of each nuc-SG primer (Eurogentec, Seraing, Belgium) and 5 μL of DNA template. A two-step real-time PCR was performed using Fast ABI 7500 (ThermoFisher) with a preincubation step at 95˚C for 20 s, followed by 35 cycles (50 cycles in sensitivity testing) of 95˚C for 3 s and 60˚C for 20 s. The PCR was completed with a melting point analysis step ramping from 60˚C to 95˚C. Amplification in hydrolysis probe PCR was carried out in a 20 μL reaction mix using 2x TaqMan Fast Advanced Master Mix (ThermoFisher), 0,5 μM of each nuc primer (Eurogentec), 0,2 μM of nuc probe (ThermoFisher) and 5 μL of DNA template. A two-step real-time PCR was performed using Fast ABI 7500 (ThermoFisher) starting with an UNG-step at 50˚C for 2 min and a pre-incubation step at 95˚C for 20 s, followed by 40 cycles (50 cycles in sensitivity testing) of 95˚C for 3 s and 60˚C for 30 s.
Secondary detection oligonucleotides and amplification conditions. nuc-SG primers used in the secondary detection were the same as in the primary detection using SybrGreen (Table 1) . Primer sequences used for mecA amplification have been previously described [14] .
Amplification of nuc and mecA was performed in parallel in the PCR instrument, but in separate reactions. The reaction mix of 20 μL contained 2x RotorGene SybrGreen (Qiagen), 0,5 μM of primers (Eurogentec), directed at nuc and mecA, and 5 μL of DNA template. A realtime PCR was performed in RotorGene 3000 (Qiagen) starting with a pre-incubation step at 95˚C for 5 min, followed by 35 cycles of 95˚C for 5 s and 60˚C for 15 s. The amplification was followed by a melting curve analysis with a ramp from 60˚C to 95˚C.
16S detection
Presence of extracted DNA from bacterial strains other than S. aureus (S1 Table) was analyzed by amplification of the 16S rDNA gene. Primers and amplification conditions have been previously described [15] . DNA presence was confirmed by analyzing quantification cycle (Cq) values and melting peaks of the amplified 16S gene.
DNA sequence analysis
Sanger sequencing. Pre-sequencing amplification was performed from CC75-08 strain DNA using nuc oligonucleotides according to the secondary detection SybrGreen PCR protocol (described in previous section). Post-amplification steps, including protocol for DNA purification and Sanger sequencing of the nuc gene, is previously described [15] . The nuc sequences obtained were first analyzed in SeqScape Software 3 version 3.0 (ThermoFisher) for species confirmation and subsequently analyzed by Nucleotide BLAST (Basic Logic Alignment Search Tool, NCBI, https://blast.ncbi.nlm.nih.gov/) and compared to open Gene Bank sequences.
Whole genome sequencing. The genome of selected clinical isolates from the method comparison study was analyzed with whole genome sequencing. Bacteria were pretreated by lysozyme (9.5 mg/mL) and lysostaphin (0.24 mg/mL) followed by extraction of genomic DNA with the EZ1 Advanced XL system using the EZ1 DNA Tissue Kit (both from Qiagen). Extracted DNA was sent to a sequencing core facility (SciLife Lab, Solna, Sweden) and sequenced using a standard operating procedure for Illumina HiSeq 2500 (Illumina, San Diego, CA, USA). In selected cases the nuc gene was mapped in silico using CLC Genomics Workbench 11 (Qiagen Bioinformatics, Aarhus, Denmark). Alignments were conducted with nuc genes from different strain sequences and the forward and reverse primers using software BioEdit Sequence Alignment Editor software, version 7.2.1 (Ibis Therapeutics, Carlsbad, CA, USA).
In silico analysis of whole genome sequences for multi locus sequence typing (MLST) and toxin genes was performed on selected clinical isolates using software from Center for Genomic Epidemiology [16] .
Experimental setup
Oligonucleotide design. For primer and probe design, the following software were used; Primer Express, version 3.0.1 (ThermoFisher) and Oligo Analyzer, version 3.1 (https://eu. idtdna.com/calc/analyzer). For the hydrolysis probe PCR oligonucleotide design, 40 unique nuc sequences from S. aureus strains were obtained from the NCBI database (https://www. ncbi.nlm.nih.gov/nucleotide) and aligned in the BioEdit software (S1 Fig) . The primer and probe sequences were complementary within the conserved regions of the nuc gene. In addition, 24 unique nuc sequences from S. argenteus strains (whereof two are defined as S. aureus in the NCBI database, but show higher resemblance to S. argenteus sequences) are presented in S2 Fig .
In experiments for oligonucleotide composition, CC75-08 tests in the hydrolysis probe PCR were performed in duplicate, while CCUG31966 data was generated from single testing.
Sensitivity study. The hydrolysis probe PCR was tested for sensitivity in comparison with the SybrGreen PCR assay. PCR was performed on DNA from CCUG31966 and the CC75-08 strain in 10-fold dilutions.
In the sensitivity test when comparing the two PCR assays in S. aureus DNA serial dilutions, both SybrGreen PCR and hydrolysis probe PCR were performed in 50 rounds of amplification and in duplicate. PCR efficiency (E) was calculated using the formula E ¼ 10 À Specificity study. Presence of extracted DNA from bacterial strains in the specificity study was confirmed by 16S amplification while DNA from viral strains in specificity study was confirmed positive by directed real-time PCR. Presence of DNA from yeast strain was not confirmed.
Method comparison study. While assessing the assay performance in clinical samples, the two primary nuc PCR assays (SybrGreen and hydrolysis probe) were tested in parallel in a method comparison study. For the purpose of facilitating ΔCq calculations between the two primary detection PCR assays, the hydrolysis probe PCR was run at 40 cycles, while the SybrGreen PCR was run at 35 cycles (as previously optimized).
Results
Separate reverse primers and a degenerated probe are required for specific amplification
During the initial part of the study, a strain from a clinical sample showed difficulties in nuc amplification, using a variety of primer combinations. A region of the nuc gene was sequenced by Sanger sequencing and analyzed using the NCBI nucleotide database. The sequenced nuc region from the clinical strain (in this manuscript named CC75-08) showed 99% similarity with the nuc gene in MSHR1132, a S. aureus CC75 lineage strain, later named S. argenteus. By aligning the nuc sequences of S. aureus and MSHR1132, oligonucleotides could be designed to fit all aligned sequences (Fig 2, EF529590.1 representing S. aureus and MSHR1132 representing the CC75 lineage/S. argenteus). All aligned sequences are illustrated in S1 and S2 Figs.
The designed nuc-F primer mismatched in position 3 at the 5'-end against the nuc gene in MSHR1132, but was identical in sequence with other aligned nuc sequences. The probe was designed degenerated in one position. As the nuc sequence at the location of the reverse primer revealed high sequence variation, separate reverse primers were designed; specific for S. aureus (nuc-R1) and specific for the CC75 strain (nuc-R2). The sequence of the two reverse primers differs at three nucleotide positions.
In the hydrolysis probe PCR, reverse primer nuc-R1 was shown to be specific and necessary for amplification of S. aureus strain CCUG31966, while nuc-R2 had little effect on nuc amplification (Fig 3A) . The opposite was observed for the CC75-08 strain (Fig 3B) . DNA amplification in both CCUG31966 and CC75-08 was successfully detected by the degenerate nuc probe. The nuc sequence in CCUG31966 and CC75-08 differ only at one position in the designed probe region. A degenerate probe was designed to obtain an adequate fluorescence from both strains during amplification (Fig 4) .
As a result of these findings, all further experiments utilizing the hydrolysis probe PCR were performed with the following oligonucleotide composition: nuc-F, nuc-R1, nuc-R2 and nuc probe (as specified in Table 1 ). This setup would include, but not differentiate, CC75-lineage strains/S. argenteus in the primary detection step.
Increased sensitivity for CC75 lineage strain/S. argenteus with the hydrolysis probe PCR All S. aureus strains (n = 25), extracted manually, were detected by the oligonucleotides in the primary hydrolysis probe PCR. None of the non-S. aureus bacterial strains (n = 29), viral strains (n = 5) or the yeast strain (n = 1), all extracted on the BioRobot M48 with DNA presence confirmed by 16S rDNA amplification or directed real-time PCR, were detected by hydrolysis probe PCR.
Plotting the Cq values against the log 10 CFU values illustrated that the PCR reaction for the primary hydrolysis probe PCR was linear over at least five orders of magnitudes for CCUG31966 and CC75-08 (Fig 5) . The lowest CFU detected per PCR reaction and the PCR efficiency were similar for CCUG31966 in the two PCR assays. However, for CC75-08, both lowest CFU detected/PCR reaction and PCR efficiency increased considerably when amplified with the hydrolysis probe PCR ( Table 2 ).
All clinical samples positive for nuc in at least one assay were subcultured. Culture showed MRSA presence in four clinical samples that were nuc positive in both SybrGreen and hydrolysis probe PCR Also, culture revealed MRSA in two additional clinical samples, originating from the same patient, with Cq values 33 and 39 in the hydrolysis probe PCR and undetected by the SybrGreen PCR. Further studies revealed that the nuc genes in these MRSA isolates were amplified using the R1 reverse primer.
Analysis of whole genome sequencing data
Whole genome sequencing was later performed on in total ten clinical MRSA isolates. One of these isolates was included in the comparison study and only detected only by the hydrolysis probe PCR, not by the SybrGreen PCR. MLST revealed that the sequence type (ST) of this isolate was 30 and it carried the virulence gene toxic shock syndrome toxin 1 (tss-1). The nuc sequence of this isolate was further analyzed and aligned together with the hydrolysis probe PCR oligonucleotides. The alignment revealed a mismatch (G 239 ! T) in the nuc-SG-F primer binding region, four nucleotides from the 3'-end. The nuc sequence was complementary to reverse primer nuc-R1 and no mismatches were found.
MLST was also performed on strain CC75-08 as well as eight isolates diagnosed as MRSA in 2013-2016 in which the nuc genes were amplified with the nuc-R2 primer (specific for the CC75 lineage/S. argenteus). Three different sequence types were observed: ST1223 (n = 5, includes CC75-08), ST2250 (n = 2) and ST2793 (n = 2), all of which belong to the CC75 lineage/S. argenteus as expected. The nuc sequence of one selected strain (ST1223) was further analyzed and aligned together with the hydrolysis probe PCR oligonucleotides. The nuc sequence was complementary to reverse primer nuc-R2 and no mismatches were found.
Increased stability with hydrolysis probe PCR
For both primary detection nuc PCR assays, PCR control Cq values (originating from CCUG31966) from over 1100 PCR reactions were documented. The plotted Cq values show an increased analytical stability for the hydrolysis probe PCR (Fig 6A) compared to primary SybrGreen PCR (Fig 6B) . The coefficient of variation was low in both assay formats, 1.69 for the hydrolysis probe PCR versus 2.18 in the SybrGreen assay.
Discussion
Herein, we describe the introduction of a new primary detection step nuc PCR, including novel oligonucleotides and hydrolysis probe. The assay allows screening of high sample volumes at a low cost with the ability to include or exclude detection of CC75 S. aureus/S. argenteus.
The final results from the screening positive samples are obtained after two further incubation days, the screening positive non-MRSA samples should therefore be kept to a minimum. In the method comparison study, the quantity of screening positive samples in the hydrolysis probe PCR varies considerably with the Cq cut-off. By lowering the Cq cut-off from 40 to 37, we could decrease the quantity of nuc positive screening samples by 25% and still maintain a high MRSA sensitivity.
In the method comparison study, the hydrolysis probe PCR detected two MRSA positive clinical samples, from the same patient, that were negative in the SybrGreen PCR. The fact that the nuc genes in these MRSA isolates were amplified using the R1 reverse primer indicates that these strains are distinct from the CC75 lineage/S. argenteus. A mismatch found in the nuc-SG-F primer binding region is the probable cause for the reduced SybrGreen PCR sensitivity towards this strain.
Despite the benefits described for the hydrolysis probe PCR, some limitations remain. The high sensitivity comes at the expense of an increased number of positive PCR results in primary detection step compared to the SybrGreen PCR. Furthermore, even though overall sensitivity was increased, the PCR still fails to detect the rare [17] cases of nuc negative MRSA strains.
The CC75 complex describes a lineage with 90% shared genome with S. aureus. It has been suggested that this lineage should be considered as a novel species, S. argenteus [13] and clinical differences have been established [18] . S. argenteus has spread internationally and share many of S. aureus virulence genes [19] . The CC75-08 strain is defined as S. aureus by standard nuc primers [13] , [this study], yet with reduced sensitivity. We have in our laboratory also found that the commercial SCCmec based test, Xpert MRSA NxG (Cepheid, Sunnyvale, CA, USA), identifies the CC75-08 strain as an MRSA. Only a few new patients are each year diagnosed with MRSA with this this lineage/species at our laboratory. The various sequence types ST1223, ST2250 and ST2793 that were defined for these strains have all previously been reported in known S. argenteus strains [18, 19] which shows that several different strains of the CC75 lineage/S. argenteus are in circulation in Sweden.
Currently, discussions are held in Sweden regarding the inclusion or exclusion of mecA positive bacteria from the CC75 lineage/S. argenteus in the MRSA definition used in the Communicable Disease Act. There is no current international consensus in this matter. In either case, most current MRSA diagnostic assays in routine practice should either increase CC75 sensitivity or omit it from the assay completely. In the assay described in this manuscript, both alternatives are possible by simply adjusting the presence of reverse primers and/or probe sequence. If desired, the assay can also easily distinguish S. argenteus from S. aureus in PCR detection by replacing the degenerated probe with specific probes with separated emission wavelengths.
By the introduction of a hydrolysis probe PCR, we are able to increase our daily MRSA screening sample capacity by 40%, up to 637 samples per day and analysis platform, with a maintained assay specificity and sensitivity. This is done at a low cost and with an assay that provides higher PCR stability, an important factor for a diagnostic laboratory in order to provide a high quality in diagnostics and a minimum of re-testing. This assay is thereby especially suitable for clinical laboratories with high sample volumes. Also, the current oligonucleotide composition increases the analytical sensitivity for the CC75 lineage/S. argenteus considerably. By minor oligonucleotide rearrangements, the assay can be customized to distinguish or completely omit CC75 lineage/S. argenteus detection, thus ensuring the accuracy of the MRSA diagnostic assay. Table. Reference strains used to test specificity. (DOCX) 
